ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has begun enrolling patients in a pivotal phase III clinical trial using pravastatin and fenofibrate to treat mixed dyslipidemia. Mixed dyslipidemia is the presence of elevated levels of “bad” cholesterol, low-density lipoproteins (LDL) and triglycerides and low levels of “good” cholesterol, high-density lipoproteins (HDL) in the blood.
